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Matrix metalloproteaseGene therapy has great potential to treat a range of different diseases, such as cancer. For that therapeutic gene
can be inserted into a plasmid vector and delivered speciﬁcally to tumor cells. The most frequently used applica-
tions utilize lipoplex and polyplex approacheswhere DNA is non-covalently condensed into nanoparticles. How-
ever, lack of in vivo efﬁcacy is the major concern that hinders translation of such gene therapeutic applications
into clinics. In this work we introduce a novel method for in vivo delivery of plasmid DNA (pDNA) and efﬁcient
tumor-speciﬁc gene induction using intravenous (i.v) administration route. To achieve this, we utilize a cell pen-
etrating peptide (CPP), PepFect14 (PF14), double functionalized with polyethylene glycol (PEG) and a matrix
metalloprotease (MMP) substrate. We show that this delivery vector effectively forms nanoparticles, where
the condensed CPP and pDNA are shielded by the PEG, in an MMP-reversible manner. Administration of the
complexes results in efﬁcient induction of gene expression speciﬁcally in tumors, avoiding normal tissues. This
strategy is a potent gene delivery platform that can be used for tumor-speciﬁc induction of a therapeutic gene.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gene therapy has great potential to treat a wide range of different
diseases which occur due to defective gene expression levels, such as
in many types of cancer. The most common way to implement gene
therapy is to deliver therapeutic geneticmaterial into cells to reestablish
protein levels by restoring or altering gene expression. However, deliv-
ery of nucleic acid-based biomolecules remains prohibitively challeng-
ing and efﬁcient, tunable/controllable [1] and non-toxic [2] delivery
vectors are required. In addition to gene transfer efﬁciency, the delivery
to tumor cells also requires tissue speciﬁcity. Nucleic acids have been
delivered to cells via different non-viral vectors; most common exam-
ples are lipoplexes and polyplexes [3]. All these are efﬁcient delivery
agents in cell cultures but translating them for in vivo applications
usually lose their effectiveness and even if ability to deliver genes is
maintained, additional modiﬁcations are needed to gain tissue speciﬁc-
ity [4,5].arge ratio; DLS, dynamic light
ffect; EtBr, ethidium bromide;
yte system; N2a, Neuro2a cells;
ylene glycol; PF14, PepFect14;
.
niversity of Tartu, Tartu 50411,
.
. This is an open access article underOne potential class of delivery vectors are cell penetrating peptides
(CPPs) [6] which can be used to non-covalently condense nucleic
acids into nanoparticles [7,8] and deliver them into cells. The ﬁrst suc-
cessful in vivo gene delivery using CPP and i.v. route was demonstrated
in 2002, although the efﬁcacies were slightly lower thanwith liposomes
or PEI and the effectswere associatedwith some toxicity [9]. According-
ly, gene delivery vector has to possess high efﬁcacy and low toxicity,
plus an additional mechanism for achieving tumor-speciﬁcity. One of
the most advanced CPP vector for tumor-speciﬁc delivery of cargo for
in vivo applications was proposed by R. Tsien's research group, where
the cell penetration activity is initiallymasked by an anionic peptide do-
main and could be reactivated via tumor-selective cleavage by matrix
metalloproteases (MMPs) [10]. Matrixmetalloproteinase 2 is a protease
engaged in the breakdown of extracellular matrix components that is
required for neoplastic growth and it is overexpressed in almost all
types of tumors, therefore being amarker ofmalignancy [11]. In the cur-
rent report we have combined a non-covalent CPP/nucleic acid com-
plexation strategy with similar CPP-shielding and tumor-speciﬁc
activation as described above. In this case, CPP is not deactivated
through an anionic domain, because this would interfere with the
CPP/nucleic acid complex formation. Instead, we use polyethylene
glycol (PEG), which serves several purposes at the same time. First,
PEG in the outer layer of the nanoparticles is a biologically inert shield
that inhibits contactswith cellmembranes, therebymasking the CPP ac-
tivity [12], a property that can later be restored in an MMP-sensitivethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ecules in the bloodstreambypostponing recognition by themononucle-
ar phagocyte system (MPS) and preventing the interactions with blood
components. Secondary to the abovementioned, PEGylation also en-
hances passive tumor targeting using the enhanced permeability and
retention (EPR) effect [13]. In this work we apply efﬁcient gene
delivery properties of PepFect14 [14] to induce high and speciﬁc gene
expression levels in tumor tissue thorough reversible inactivation strat-
egy. We show that using this method, efﬁcient and tumor-selective
gene induction is achieved.
2. Material and methods
2.1. Synthesis of peptides
All peptides were synthesized in a stepwise manner in a 0.1 mmol
scale on an automated peptide synthesizer (Applied Biosystems,
ABI433A) by using standard protocols for Fmoc solid-phase synthesis.
Rink-amide MBHA resin (Orpegen, Germany) was used as the solid
phase to obtain C-terminally amidated peptides. N-terminally
stearylated peptides were prepared by treatment of peptidyl resin
with 4 equiv. of stearic acid (Sigma-Aldrich), 4 equiv. of HOBt/HBTU
(MultiSynTech), and 8 equiv. of DIEA (Sigma-Aldrich) in DMF/DCM for
18 h. C-terminally PEGylated peptides were prepared by treatment of
Rink-amide MBHA resin with 2 equiv. of Fmoc-PEGn-CH2CH2COOH
(PEG1000, PEG2000 — JenKem, USA, PEG600 — Chempep, USA), 2
equiv. of HOBt/HBTU and 4 equiv. of DIEA in DMF/DCM for 24 h which
was followed by standard Fmoc peptide synthesis. The ﬁnal cleavage
was performed using a standard protocol [95% triﬂuoroacetic acid
(TFA)/2.5% TIS/2.5% water] for 2 h at room temperature. Peptides
were puriﬁed by RP-HPLC using a C3 column and 5–80% acetonitrile
(0.1% TFA) gradient. Molecular weight of the peptides was analyzed
by MALDI-TOF mass-spectrometry, and purities were N90% as deter-
mined by analytical HPLC.
2.2. Complex formation
For complex formation, stability and cell culture assays 0.5 μg of
pLuc2 plasmid was mixed with CPPs at different peptide:pDNA charge
ratios (CR) inMQwater in 50 μl (1/10th of the ﬁnal treatment volume).
CRs were calculated theoretically, taking into account the positive
charges of the peptide and negative charges of the pDNA. In order to
form complexes at different PEGylation rates, PEGylated peptide was
ﬁrstlymixedwith pDNA and thereupon PF14was added and complexes
were formed by incubating 40 min at room temperature. PEGylation
rate is deﬁned as the amount of PF14 which is substituted with its
PEGylated PF14 analog, for example, PEGylation rate 20% represents
complexes with 80% of PF14 and 20% corresponds to PEGylated PF14
analog.
For in vivo studies 20 μg of pLuc2 per animal (0.8 mg/kg) wasmixed
with 1 mM peptide at CR2 or CR4 in MQ water and the volume of com-
plexes was kept constantly at 100 μl. For PEGylated complexes, ﬁrst
CPP-PEG was mixed with pDNA in MQ water and incubated for 5 min
followed by addition of parent CPP. After 40 min of incubation 100 μl
of 10% glucose was added to preformed complexes and immediately
injected intravenously via tail vein.
2.3. Gel shift and EtBr exclusion assay
pDNA condensation and incorporation into complexeswas analyzed
using a gel shift assay and ethidium bromide (EtBr) (Sigma, Sweden)
exclusion assay. Brieﬂy, for both assays, complexes were formed as
described above. For gel shift assay, samples were electrophoresed on
agarose gel (1%) in TAE (1×) and imaged by staining the gel with EtBr
(0.5 μg/ml). Gels were visualized using the UVIpro Gold Gel Documen-
tation System (United Kingdom). In the EtBr exclusion assay, after40 min. of incubation, 165 μl of MQ water was added to each complex
sample (20 μl) and transferred into a black 96-well plate (NUNC,
Sweden). Thereafter, 15 μl (5.33 μg/ml) of EtBr solution was added to
give a ﬁnal EtBr concentration of 400 nM. After 15min, the ﬂuorescence
was measured on a Spectra Max Gemini XS ﬂuorometer (Molecular
Devices, Palo Alto, CA) at λex = 518 nm and λem = 605 nm. Results
are expressed as relative ﬂuorescence and a value of 100% is attributed
to the ﬂuorescence of naked pDNA with EtBr.
2.4. Heparin displacement assay
For the analysis of peptide/pDNA or peptide/Cy5-labeled pDNA
complexes resistance to heparin, preformed peptide/pDNA complexes
containing 100 ng of plasmid DNA were incubated for 30 min at 37 °C
in the presence of heparin sodium (Sigma-Aldrich, Germany) over a
range of concentrations. After the incubation period, reactions were an-
alyzed by EtBr exclusion assay or by gel shift assay which are described
above. Results are expressed as relative ﬂuorescence, where 100% is the
ﬂuorescence of naked pDNA
2.5. Enzymatic stability
The resistance against degradative enzymes such as proteases and
nucleases was evaluated using fetal bovine serum (FBS, Life Technolo-
gies, USA) and DNase I (Thermo Scientiﬁc, USA). For serum stability
assay, complexes were formed as described above and 10% of FBS was
added to complexes and as a control accordingly the same amount of
MQ water was added to complexes. Thereafter complexes were incu-
bated for 2 or 4 h at 37 °C and then analyzed by gel shift assay
(described above) or used for transfection as described in plasmid deliv-
ery section. In the case of nuclease stability assay, 12.5 μl of DNase I in
buffer (as instructed in the protocol by the manufacturer) or same
amount of buffer alone was added to complexes (1.05 μg pDNA dose
at CR2 or CR4, DNase ﬁnal concentration was 0.02 U/μl). Treatment
was carried out for 30 min. at 37 °C and thereafter complexes were an-
alyzed by gel shift assay and used for plasmid delivery assay described
in plasmid delivery assay section. In order to visualize degradation of
pDNA, proteinase K treatment was carried out. Complexes or naked
pDNA were incubated with 20 μg of proteinase K (Thermo Scientiﬁc,
USA) for 30 min at 37 °C and thereafter analyzed by gel shift assay.
2.6. Dynamic light scattering (DLS) measurements
Hydrodynamic mean diameter of the DNA nanoparticles was deter-
mined by dynamic light scattering studies using a Zetasizer Nano ZS ap-
paratus (Malvern Instruments, United Kingdom). Peptide/pDNA
complexes were formulated according to the protocol for in vitro trans-
fection, as described above, and assessed in disposable low volume cu-
vettes. Brieﬂy, pDNA complexes were formulated in MQ water, in
100 μl volume, at a ﬁnal concentration of 0.01 μg/μl of pDNA. After
40 min of incubation at room temperature complexes were measured
or glucose (ﬁnal concentration 5%) was added. Measurements were
performed at over a period of time and at RT, for each sample (n = 2)
3 measurements were made and 1 measurement was set to 10 runs
(1 run was 10 s). For zeta potential measurements pDNA complexes
were formulated inMQwater, in 300 μl volume, at a ﬁnal concentration
of 0.01 μg/μl of pDNA. After 40min incubation at room temperature, the
complexeswere diluted inMQor glucose (ﬁnal concentration 5%) into a
ﬁnal volume of 1 ml. Measurements were performed at over a period of
time and at RT, for each sample (n= 1–2) 3 measurements were made
and 1 measurement was set to 10 runs.
2.7. Cell culture
CHO cells were grown in humidiﬁed environment at 37 °C, 5% CO2
and cultivated in Dulbecco's Modiﬁed Eagle's Medium F12 (DMEM-
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acids, 1.0 mM sodium pyruvate, 10% FBS, 100 U/ml penicillin and
100 μg/ml streptomycin (PAA Laboratories GmbH, Germany). U87 and
Neuro2a and cells were grown in humidiﬁed environment at 37 °C, 5%
CO2 and cultivated in DMEM with glutamax supplemented with
0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate, 10% FBS,
100 U/ml penicillin and 100 μg/ml streptomycin.2.8. Plasmid delivery assay
4 × 104 CHO or 5 × 104 U87 cells or 3 × 104 Neuro2a cells were seed-
ed 24 h before experiment into 24-well plates. Cells were treated with
peptide/pDNA complexes at CR2 or CR4 for 4 h in serum containing
media, followed by addition of 1 ml 10% serum containing medium
and incubated for another 20 h. Thereafter, cells were lysed using
100 μl 0.1% Triton X-100 in PBS for 15 min at 4 °C. Luciferase activity
was measured using Promega's luciferase assay system according to
the manufacturer's protocol on GLOMAX™ 96 microplate luminometer
(Promega, Sweden) and normalized to protein content (BioRad Protein
Assay, USA).
To study the effect of MMP2 cleavage to transfection efﬁciency, pep-
tide/pDNA complexes were preincubated with an active recombinant
MMP2 (0.1 mg/ml, Calbiochem, Germany) for 30 min at 37 °C and
then proceeded with transfection as described above. Thereafter, cellsFig. 1. Biological activity of PF14 in vivo in different tissues. (A) The ability of PF14/pDNA compl
with 20 μg of pLuc2 plasmidwere administered intravenously via the tail vein. After 24 h, tissues
normalized to the protein content. Values are represented as fold increase of RLU/mgover the pD
of CR2 and CR4 against pDNA group. *p b .05, **p b .01, ***p b .001. N = 6–10 in each group. (B
complexes were mixed at CR4, using 5–20 μg of pLuc2 plasmid. N= 2–4 in each group. (C) The
parent CPP, PF14 was C-terminally modiﬁedwith PEG using anMMP2-sensitive peptide linker
cationic CPP (PF14) and anionic DNA. A proportion of the CPP is substituted to PEGylated CPP, an
shield that inhibits transfection until cleaved by a tumor-speciﬁc MMP2. After this an active pawere washed with 1 × PBS and lysed as described above. Luciferase
activity was measured and normalized to protein content.
2.9. Cell proliferation assay
Cell proliferation was studied with MTS proliferation assay (Promega,
Sweden). Brieﬂy, 1 × 104 cells were seeded 1 day before treatment into a
96-well plate (Greiner Bio One, Germany). Cells were treated with pep-
tide/pDNA complexes at CR2 andwith different PEGylation rate;, howev-
er, to optimize the amounts to ﬁt a 96-well format, 5 times less pDNA and
peptide inMQwaterwas used compared to 24-well plates. After 4 h fresh
media (200 μl) was added and 24 h later MTS reagent was added and ab-
sorbancewasmeasured after 2 h of incubationwith Tecan Sunrisemicro-
plate reader (Tecan Trading AG, Switzerland). Untreated or pDNA-treated
cells were deﬁned as 100% viable.
2.10. Tumor induction
All animal experiments and procedures were approved by the
Estonian Laboratory Animal Ethics Committee (approval nos. 69 and
70, dated Feb 9, 2011).
The mouse Neuro2a tumors were induced in BALB/c mice subcuta-
neously (s.c.). Human tumor xenografts were induced in nude animals
(Hsd: Athymic Nude-Foxn1nu female, 4–6 week old, Harlan, UK). The
tumors were induced by resuspending 1 × 106 cells in 100 μl volumeexes to induce gene expression levels in different tissues was evaluated in vivo. Complexes
were harvested, homogenized, and lysed. Thereafter, luciferase activitywasmeasured and
NA treated group. Stars represent p-values fromKruskal–Wallis comparison of RLU values
) To evaluate the ability of complexes to induce gene expression at different pDNA doses,
schematic construction principle of a tumor-targeted CPP/nucleic acid nanocomplex. The
between the CPP and PEGmoieties. Hypothetically, the core of the complex consists of the
d, according to our hypothesis, PEG orients itself as an outer shell which provides a neutral
rticle is generated.
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performed by implanting the cell suspension subcutaneously to the
right ﬂank. At the appearance of the ﬁrst signs of tumor growth (for
the subcutaneous tumors, tumor size of approximately 100 mm3),
micewere injected i.v. (via tail vein)with the peptide/pDNA complexes.2.11. Quantitation of luciferase levels and ﬂuorescence from tissues
24 h after administration of complexes the mice were sacriﬁced
using cervical dislocation and tissues were harvested and snap-frozen
on dry ice. The tissues were homogenized using Precellys®24-Dual ho-
mogenization system (Bertin Technologies, France) and lysed using
1 × Promega lysis buffer (Promega, Sweden). Luciferase content was
analyzed as described previously [15]. Brieﬂy, homogenized tissues
were thawed and 500 μl of Promega Reporter lysis 1 × buffer was
added. The samples were subsequently vortexed for 15 min, subjected
to 3 consecutive freeze–thaw cycles (liquid nitrogen and 37 °C water
bath), centrifuged for 3 min at 10 000 g, 4 °C; supernatant removed
and saved for later analysis. 500 μl of lysis buffer was again added to
the pellet and the extraction process repeated (without freeze–thaw cy-
cles). The second supernatant was combined with the ﬁrst one and was
subjected to luciferase activity assay or for ﬂuorescence measurements.
Firstly, luciferase was measured with Promega luciferase assay system,
in combination with GLOMAX 96 microplate luminometer (Promega,
Sweden). Accordingly, 20 μl of the supernatant was transferred to the
white 96-well plate and 80 μl of luciferase substrate was added to
each sample. An average LU (light unit) out of 3 technical replicates
was used for data analysis. The LU values within each sample were nor-
malized to protein content (BioRad, United States) and the resultant
RLU/mg were normalized to the corresponding tissue of the animals
that received naked pDNA injection (sham treatment). For Cy5-
labeled pDNAﬂuorescencemeasurements 100 μl of sampleswere trans-
ferred to black 96-well plate (NUNC, Sweden). Then, the ﬂuorescence
was measured on a Spectra Max Gemini XS ﬂuorometer (Molecular
Devices, Palo Alto, CA) at λex = 650 nm and λem= 670 nm. An average
FU (ﬂuorescence unit) out of 3 technical replicates was used for data
analysis. The FU values within each sample were normalized to protein
content (BioRad, United States) to get RFU/mg.Table 1
Peptides sequences and the modiﬁcations used.
Name Construction principle
PepFect14
PepFect141 PF14-PEG600 (1)
PepFect142 PF14-PEG1000 (2)
PepFect143 PF14-PEG2000 (2)
PepFect144 PF14-MMP2-PEG600
PepFect145 PF14-MMP2-PEG1000
PepFect146 PF14-MMP2-PEG2000
PepFect147 PF14-scrMMP2-PEG600
PepFect148 PF14-scrMMP2-PEG1000
PepFect149 PF14-scrMMP2-PEG2000
(1) Monodisperse PEG, PEG size indicated by the molecular mass.
(2) Polydisperse PEG, PEG size indicated by the average molecular mass.2.12. Quantitation of ﬂuorescence from blood
Complex stability in blood was studied using Cy5-labeled pDNA
(Mirus, USA), where 20 μg labeled pDNA was mixed with the peptides
and injected as described above. Blood was collected at different time
points (0,5 h–6 h) from saphenous vein using sodium-heparinized
(80 iu/ml ± 30%) capillaries (Marienfeld, Germany;, thereafter, blood
was transferred to heparinized blood collecting tubes (Sarstedt,
Germany) and stored at−20 °C until the analysis. Then 20 μl of blood
was transferred to a black 96-well plate and the sample was diluted 5
times in MQwater. Cy5-pDNA ﬂuorescence was measured on a Spectra
Max Gemini XS ﬂuorometer (Molecular Devices, Palo Alto, CA) at λex=
650 nm and λem = 670 nm and the ﬂuorescence of untreated sample
was subtracted. Acquired values were normalized to pDNA concentra-
tion which was calculated based on naked pDNA or peptide/pDNA
complex calibration curves.3. Results and discussion
3.1. Optimizing PF14 / pDNA formulations for in vivo use
Wehave shown earlier that PF14 is an efﬁcient gene transport vector
in cell cultures [14] but its gene delivery potential has not yet been eval-
uated in vivo conditions. To test thiswe complexed peptidewith a pluc2
gene expressing vector and administered systemically via intravenous
(i.v.) administration route. PF14-mediated gene delivery induces lucif-
erase expression in various organs, particularly in lungs, where luciferase
levels reach up to 3 logs over control (naked pDNA) levels (Fig. 1A). How-
ever, we occasionally observed acute toxic reactions occurringwith PF14/
pDNA (20 μg dose) at CR4, where about 1 out of 15 animals died within
10 min after injection. We hypothesize that the complexes of PF14 may
aggregate upon contact with blood, as shown earlier with cationic lipo-
some/pDNA [16] or with polyplex/pDNA [17]. This suggests that some
factors during the formation of complexes need to be addressed to
achieve their potential for use in vivo. When comparing different charge
ratios, CR4 is more efﬁcient than CR2, an effect that is especially apparent
in the lungs and liver. In addition, the minimal effective dose of pDNA is
20 μg per animal (0.8 mg/kg) (Fig. 1B).Sequence
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3.2.1. Characterization of PEGylated peptide/pDNA complexes
We next intended to explore the possibility of using PEG as a shield
to inactivate the CPP activity, because PEGylation has the potential to in-
crease general in vivo usability by inhibiting unwanted contacts with
blood proteins and cells. To functionalize PF14 with PEG, a series of
PF14 analogs were synthesized, where PEG with 3 different chain
lengths (PEG600, PEG1000 and PEG2000) was covalently conjugated
to the C-terminus (Table 1, Fig. 1C). We named these PF141, PF142
and PF143, respectively. Our hypothesis was that the functionalized
PF14 would still retain the complex formation ability with the core of
the particle being formed by the cationic peptide and anionic DNA and
the PEG would orient itself as an outer shell and act as a moiety that
would mask the transfection ability of CPP. Later, delivery can be re-
stored only to speciﬁc tissues in a controllable manner. Accordingly,
the two crucial questions for us were: can the complexes be formed
and does the PEG form an outer shell?
We ﬁrst assessed the ability of PEGylated peptides to form stable
complexes with pDNA. For that, we carried out a gel shift assay where             CR2    10%     20%     40%     60%    80%    100%
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showed the highest quenching of EtBr (the plateau is reached already
at CR1, Fig. S1B), whereas PF14 and PF141 reached the plateau at CR2
and CR3 (Figs. 2B, S2B). PF142 formed less condensed complexes
(Fig. S3B).
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Hypothetically, more favorable therapeutic properties may be
achieved with complexes that have adjustable amounts of PEG; there-
fore, we were interested in modifying the functionalization rate of
complexes and for that we tested an alternative approach, where a
proportion of the CPP-PEG would be substituted with the parent0% 10
%
20
%
40
%
60
%
80
%
10
0%
0
3000
6000
9000 PF141 PF142 PF143
Pegylation rate
(ov
er
pD
NA
tre
at
ed
)
CHO cells
CR
2
0,3
12
5
0,6
25 1,2
5 2,5 5 10
0
25
50
75
100
125 PF14 PF141 (40%) PF142 (40%) PF143 (40%)
Heparin sodium (mg/ml)
Re
la
tiv
e
flu
o
re
sc
en
ce
(%
o
fn
ak
ed
pD
NA
)
CR
2
0,3
12
5
0,6
25 1,2
5 2,5 5 10
0
25
50
75
100
125 PF14 PF141 (100%) PF142 (100%) PF143 (100%)
Heparin sodium (mg/ml)
Re
la
tiv
e
flu
o
re
sc
en
ce
(%
o
fn
ak
ed
pD
NA
)
C
D
E
. (A) Complex formation at increasing range of PEGylation ratewas assessedwith a gel shift
sion assay. PEGylation rate 0% represents PF14/pDNA complexes formed atCR2. Results are
displacement assay was used to analyze the stability and dissociation proﬁle of PEGylated
resented as relative ﬂuorescence with EtBr, where 100% is naked pDNA ﬂuorescence.
in CHO cells at CR2 and at different PEGylation rates. For that luciferase encoding pDNA
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functionalization rate (Fig. 1C). We prepared a series of complexes,
consisting of 3 different components: CPP, CPP-PEG and pDNA, and
titrated the ratio of CPP to CPP-PEG. To characterize the amount of
PEGylated peptide containing within the complexes, we use the term
PEGylation rate, which is deﬁned as the amount of PF14 that is
substituted with its PEGylated analog. For example, a PEGylation rate
of 20% means that 20% of the cationic charges arise from the PEGylated
peptide.
Importantly, we observed that complexes formedwith CPP and CPP-
PEG incorporated and condensed pDNA. At lower CR, a higher
PEGylation rate correlatedwith lower pDNA incorporation and conden-
sation. Curiously, complexes with PF142 (PEG1000) tended to be less
condensed (Fig. S3B) and less pDNA (Fig. 2A) was incorporated into
complexes. PF141 and PF143 fully incorporated pDNA starting from
CR2, although PF143 formed more condensed complexes already at
lower CRs (Fig. 2A and B). This indicates that a lower concentration of
PF143 is required to condense the same amount of pDNA, while PF141
complexes, at least at higher PEGylation rates, are not able to condense
pDNA as efﬁciently. PF142 fully incorporates pDNA only at higher CR,
and even then the complexes remain loose, which is surprising consid-
ering that complexes with the smallest and the largest PEGs (PEG600
and PEG2000) appear to be more condensed than with the middle-
sized PEG (PEG1000). We hypothesize that PEG600 in PF141 is small
enough to be incorporated into the complex core to a small extent,
resulting in more loose interactions between cationic CPP and anionic
pDNA. In contrast, PF142 is able to incorporate pDNA into complexes
only at lower PEGylation rates, when increasing the PEGylated peptide
content, a free pDNA fraction is observed (Fig. 2A). It may be that
PEG1000 in PF142 at high PEGylation rate complexesmay also be incor-
porated into the particle core to a small extent; however, PEG1000 is
large enough to prevent complex formation in these situations. There-
fore, it seems that in the case of PEG600 and PEG1000, complex stability
largely depends on PEGylation rate, where increasing the proportion of
PEG gradually destabilizes the complex. PEG2000 in PF143 on the other
hand is large enough that it forms a stable outer PEG layer, yielding the
most condensed complexes.
To compare the strength of complexes we used a heparin displace-
ment assay [7]. Accordingly, the PEG-functionalized complexes were
weaker than parent PF14/pDNA complexes at CR2 (Fig. 2D). When
increasing the CR to 4, differences between the PEG sizes during com-
plex formation become apparent: complexes with PF143 possessed
theweakest pDNA complexation ability, while PF141 and PF142 formed
stronger complexes (Fig. S3D). To understand to what degree the
PEGylation rate alters the stability of the complexes, we analyzed
PF14/PF14-PEG complexes. PF14 and its analogs PF142 and PF143
with a PEGylation rate of 40% formed similarly condensed
nanocomplexes at CR2 and CR4 (Figs. 2C and S3C). Therefore, heparin
treatment was carried out using those conditions. We saw that
PF142 at CR2 forms more similar complexes to PF14 than PF143,
where the latter forms weaker complexes (Fig. 2C). Overall, mixing
the parent peptide with PEGylated peptides increases the stability of
PEGylated complexes and at CR4, a higher concentration of heparin
was required to partially release pDNA (Fig. S3C).
To determine the PEGylated peptide/pDNA complex size and surface
charge DLS measurements were carried out. All PEGylated peptide/
pDNA complexes remained in the range of 100–200 nm (Table S1)
and displayed positive surface charge between 28 and 48 mV
(Table S2). It appeared that complexation of pDNA with peptide carry-
ing a higher molecular weight PEG (PF143, PF146 and PF149), a slight
shift of surface charge occurring from about 45 to 30 mV. Peptides car-
rying smaller PEGs did not have signiﬁcant change in surface charge.
Adding glucose (ﬁnal concentration 5%) to preformed complexes
increased heterogeneity and the average size of PEGylated complexes
increased to 150–250 nm (Table S1). No signiﬁcant differences between
peptides carrying increasing PEG chains were observed. This couldindicate that higher molecular weight PEG chains are needed to make
complexesmore homogenous [18]. Intriguingly, adding glucose to com-
plexes turned zeta potential more neutral, but overall surface charge
remained positive. The results also suggest that increasing PEGylation
rate turned the surface charge more neutral in the presence of glucose.
For example, 100% of PF141 inMQwater had surface charge 41mV, but
in the presence of glucose it shifted to 17 mV, reducing almost two
times, an effect which could be seen in the case of other PEGylated
peptide/pDNA complexes as well (Table S2).
Because our initial goal was to shield transfection properties of PF14
using PEG, we studied the effect of PEGylation to gene delivery efﬁcien-
cy. From Fig. 2E, we see that regardless of the PEG size, 100% PEGylated
peptide/pDNA complexes showed zero transfection activity. When de-
creasing PEGylated peptide content in complexes, transfection ability
was restored in a concentration dependent manner (Fig. 2E, 2-way
ANOVA “PEGylation rate” F(6, 123) = 14.53, p b .0001).
In conclusion, complex formation and characterization studies
showed that PEGylated analogs of PF14 were able to incorporate and
condense pDNA into complexes and that simply mixing the parent
PF14 with PEGylated peptides is an effective, simple, and ﬂexible
approach to prepare noncovalent functionalized CPP/nucleic acid
complexes at any PEGylation rate, yielding complexes that are both
stable and retain the ability to partially release pDNA. Finally, PEG as a
shield has a potential to mask transfection ability of PF14.
3.2.3. The resistance of PEGylated peptide/pDNA complexes to degradative
enzymes
One requirement for gene delivery vectors is to protect their cargo
from degradative enzymes such as nucleases and proteases. To assess
these properties we analyzed serum treated particles with gel shift
assay and subsequently evaluated their transfection ability in cells to
determine how much transfection efﬁciency remained. Not surprising-
ly, we saw that naked pDNA is susceptible to serum degradation but
complexation with PF14 is able to protect pDNA, at least partially
(Fig. S4A, B). Similar pDNA protective effect was seen when small
amount (10% and 20%) of PF14was substitutedwith PEGylated peptides
(Fig. S4A, B).
We next transfected cells with the serum treated complexes. Not
surprisingly, PF14/pDNA complexes were resistant to serum degrada-
tive enzymes (Fig. S4C) even after 4 h of incubation with FBS
(Fig. S4D). However, PEGylated complexes were less efﬁcient in trans-
fection efﬁcacy (Fig. S4C and D). We replicated similar in vitro stability
tests using higher PEGylation rate (40%) and a more straightforward
assay with nuclease, DNase I. As expected, all of the free pDNA was de-
graded by the nuclease treatment (Fig. 3A). At CR2, PF14 and PEG-PF14
protected pDNA to a small extent. Using peptides at CR4 offered more
efﬁcient protection against the nuclease activity, especially in the case
of PF14 and PF141 (Fig. 3A). Finally, when cells were transfected with
the DNase pretreated complexes, neither PF14 nor PEG-PF14 were
affected by the nuclease treatment (Fig. 3B). To sum up, compared to
PF14/pDNA complexes, formulations with PEGylated peptides seem to
be slightly less stable according to DNA protection ability and transfec-
tion efﬁcacy after degradative challenge. Although these results suggest
smaller complex stability in degradative environment, it does not
exclude the possibility that slightly decreased stability in such environ-
ments could contribute higher gene induction. Also, there are other
important factors that determine in vivo efﬁcacy, such as potential
aggregation and immune activation.
3.2.4. Characterization of PEGylated peptide/pDNA complexes in vivo
Next we tested the efﬁcacies of PEGylated complexes in vivo condi-
tions. Firstlywe determined the availability of nanocomplexes after 24h
of administration, for that the biodistribution of PF14/pDNA and
PEGylated PF14/pDNA complexes were evaluated. We complexed
Cy5-labeled pDNA with the peptides and analyzed the ﬂuorescence
content in different tissues. Prior to administration we assessed if Cy5-
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pDNA and conﬁrmed no major differences (Fig. S5A–C). The only
observed difference was that PF142 and PF143 complexes with Cy5-
pDNA dissociated less in the presence of the highest concentration of
heparin, a possible modulating effect to hydrophobicity of the Cy5
dye. Nevertheless, both themodiﬁed and unmodiﬁed pDNAwere incor-
porated into similar complexes. After administration of complexes it
was seen clearly that PEGylation altered biodistribution of the com-
plexes. While not surprising, complexation of pDNAwith PF14 enriches
the signal in the lungs (as also suggested by their ability to induce luc
gene in the lungs), the complexes with PF142 and PF143 showedmark-
edly lower lung accumulation (Fig. 4A). Secondly, PEGylation seems to
increase their distribution in other tissues. We hypothesize that
PEGylation could reduce complex accumulation in lung tissue and
therefore they are more available to other tissues. For example,
compared with PF14/pDNA complexes, PEGylation increased the
accumulation of complexes in the spleen and heart (Fig. 4A). To assess
the pharmacokinetic effect of PEGylation, Cy5-pDNA levels in blood
was measured at several time points after the injection. As can be seen
in Fig. 4B, naked pDNA is cleared already 1 h postinjection, while the
CPP-complexed pDNA persists for 3 h (p b .01, Tukey post-hoc pDNA
group versus PF141 or PF142, ANOVA F(10, 71) = 2.89, p b .01). More-
over, PEGylation further decreases the rate of elimination, because the
levels of PEGylated pDNA/PF14 complexes reach up to 2 times higher,
compared with complexes without PEG (p b .011, Tukey post-hoc
PF141 group versus PF14). This suggests that functionalization of com-
plexes with PEG inhibits their contact with blood serum elements,
and/or PEGylation inhibits high lung accumulation, resulting in a longer
circulation half-life.
We characterized the ability of PEGylated peptide/pDNA complexes
to induce gene expression using PEGylation rates from 10% to 60% and
CR4. As with the in vitro experiments, the aimwas to titrate PEGylation
rate and assess its inhibiting effect on gene induction.We observed that
PF141 (PEG600) was less efﬁcient in gene induction compared with
either PF142 (PEG1000) or PF143 (PEG2000) (Fig. 4C). For all the pep-
tides, increasing the PEG content gradually decreased gene expression
levels in the lungs, reaching the zero level at 60% PEGylation rate. PEG
shielding effect is apparent and in accordance with in vitro transfection
proﬁles. The smaller efﬁcacy of PF141 could be caused by less stable
complexes. Particle characterization (Fig. 2) showed that PEG600 in
PF141 results in more loose complexes, compared with larger PEG
analogs. Importantly, none of the PEGylated PF14/pDNA complexes
exhibited the occasional toxicity that we observed in the case of non-
PEGylated particles, further favoring their in vivo use.
An obvious question when adding a PEG shield to a delivery vector
is: How does this inﬂuence temporal gene induction? Accordingly,
PEG maywell prolong the complex circulation time and gene induction
may be induced at a later time point. We therefore assessed the induc-
tion of the luc gene at a later time point. Nevertheless, this proved not to
be the case, because the gene expression levels with or without PEG
showed a similar decline in time, and in both cases luc expression levels
returned to baseline within 48 h after the injection (Fig. S6A–B). Never-
theless, the gene induction efﬁcacy depends on both the delivery efﬁca-
cy and the properties of the expression vector. Thus, conclusive remarks
can be drawn after assessing the inﬂuence of pDNAelements such as the
presence of a CMV promoter [19], CpG patterns [20], etc.
These observations support our initial hypothesis that PEG is able to
form a shielding barrier between the active core and outer environment
(Fig. 1C), thereby providing advantages that are crucial for in vivo appli-
cations. Pegylation increases blood circulation half-life (Fig. 4B), which
can be used to yield a more favorable delivery efﬁcacy. It may also
provide protection from immune system recognition and subsequent
unfavorable reactions. Indeed, we did not observe any toxic reactions
with any of the PEGylated PF14/pDNA particles. Second, PEGylation
inactivates the high transfection ability of PF14, which may seem to be
a contradictory goal when developing an efﬁcient delivery vector.However, PEG can be conjugated via small and functional linkers that
can be cleaved upon fulﬁllment of certain environmental criteria,
such as in the presence of tumor-speciﬁc extracellular proteases
[21], which could allow for controllable gene induction speciﬁcally in
tumors.
3.3. Construction of tumor-sensitive pDNA delivery vector
3.3.1. Passive accumulation of peptide/pDNA complexes in tumors
Because our goal was to develop a tumor-activatable gene delivery
platform, we ﬁrst assessed the behavior of the unmodiﬁed parent CPP.
Therefore, we investigated if PF14/pDNA complexes were able to pas-
sively accumulate inside tumors and induce gene expression. For that
we induced subcutaneous tumors from human glioblastoma cell line
U87. We observed that PF14/pDNA complexes were not able to trigger
signiﬁcant gene expression in tumors (Fig. 4D) 24 h postinjection,
although the complexes are able to transfect cells in vitro [14]. We
speculate that PF14/pDNA complexes are quickly cleared from blood
circulation and therefore are not passively accumulating in tumors
and could not be taken up by tumor cells. In addition, PF14/pDNA
complexes displayed more gene induction in the lungs (Fig. 1A)
where luciferase expression was at least 10 times higher than in other
tissues. It may be that the majority of complexes are rapidly taken up
by the lungs and thus interfere with passive accumulation within
tumors.
The PF14/pDNA complexes failed to accumulate to tumors and
displayed high gene induction in the lungs,whereas the PEGylated com-
plexes displayed altered biodistribution (Fig. 4A) and prolonged circula-
tion time (Fig. 4B). Therefore, our hypothesis was that these particles
could passively accumulate in tumors through the EPR effect. Indeed,
we observed that adding PEG prevented high lung gene induction,
while at the same time possibly even enhancing gene induction in
other organs (Fig. 4C). We therefore assessed the gene delivery efﬁcacy
of CPP-PEG in U87 tumor bearing mice. Intriguingly, even a 10%
PEGylation rate induced signiﬁcant gene expression in tumors, reaching
up to 7-fold over pDNA treatment (Fig. 4D). We decided that it is suit-
able to proceedwith tumor-speciﬁc targeting and add furthermodiﬁca-
tions to the characterized PEGylated PF14 analogs.
3.3.2. Construction of MMP2-sensitive particles
Next, we reasoned that if PEGylation of the complexes enables us to
decrease PF14 gene induction in the lungs and improve tumor delivery
(Fig. 4D), the tumor speciﬁcity could potentially be increased if a tumor-
speciﬁc cleavable linker were introduced between PEG and CPP moie-
ties (Fig. 1C). Conceivably, a combination of higher PEGylation rate
and cleavable PEG in complexes would inhibit general uptake in tissues
and provide tumor-speciﬁc gene induction. In this way the particle
properties would depend on the conditions of the extracellular environ-
ment and PEG could be removed after passive accumulation near tumor
cells, thereby enhancing speciﬁc gene induction. The tumor-speciﬁc en-
vironmental conditions could be pH [22] or temperature [23]. However,
there are several successful reports on carriers that depend on tumor-
speciﬁc enzymatic cleavage [21,24]. Therefore, we introduced an extra
MMP2-cleavable linker to PEGylated PF14 analogs (Table 1) and
assessed their tumor-speciﬁc gene induction. PEG moieties with differ-
ent molecular weights were covalently attached to the C-terminal end
of PF14 peptide through an MMP2-cleavable sequence [11]. A scram-
bled MMP2 cleavable sequence was used as a negative control. A
PEGylation rate of 50%was chosen because at this rate transfection efﬁ-
ciency was entirely masked in vitro (Fig. 2E); however, complexes still
formed and pDNA was condensed (Figs. 2, S3). Furthermore, at 50%
PEGylation, in vivo, gene induction was inhibited for all PEG sizes
(Fig. 4C).
To validate MMP2 enzyme cleavability, peptides were digested with
recombinantMMP2 enzyme and thereafter analyzed by RP-UPLC. Chro-
matograms showed that near complete cleavage was accomplished
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while the peak of PF147 (uncleavable PEG600) did not disappear after
MMP2 digestion (Fig. S7).
Thereafter we conducted experiments ﬁrst in cell culture, using
Neuro2a and U87 cell lines, comparing the MMP2 sensitive PEGylated
peptides with their respective uncleavable peptides. To assess the effect
of MMP2 activation on transfection, the complexes were preincubated
with the MMP enzyme. Consistent with our hypothesis, MMP-treated
complexes were able to induce gene expression levels comparable to
that of PF14/pDNA in U87 cells (Fig. 5A), while the complexes not incu-
bated with the enzyme did not induce signiﬁcant gene expression,similar to complexes made with uncleavable peptides. Similar results
were obtained in Neuro2A cells (Fig. S8C). We also veriﬁed that neither
the PEGylated peptides nor MMP2 enzyme induced toxic effects on the
cells by carrying out a cell viability assay (Fig. S8A, B). We next titrated
the PEG% inMMP2-sensitive complexes and observed that regardless of
the PEGylation rate, the efﬁcacy of the preactivated complexes reached
at least the same levels as PF14/pDNA (Fig. 5B). In the case of 50% PEG in
PF144, the gene expression levels were even one log higher. It seems
that PEGylation does not hinder the accessibility of MMP2 enzyme
(at least in vitro), which is important for tumor-speciﬁc activation of
these complexes. Nevertheless, we hypothesize that in vivo MMP2
247K.-L. Veiman et al. / Journal of Controlled Release 209 (2015) 238–247levels are much lower than the level used here (even in highly malig-
nant tumors) and increasing the PEGylation rate could decrease efﬁcacy
due to insufﬁcient activation by the protease.
We proceeded with a 50% PEGylation rate, using PF144/PF14 com-
plexes for in vivo evaluations. Accordingly, reporter gene expression
was greatly reduced in the lungs, yet signiﬁcantly increased in Neuro2a
tumors at 50% PEGylation (Fig. 5C). Furthermore, increasing PEGylation
rate up to 70% permitted gene induction speciﬁcally in tumors, leaving
luciferase levels to baseline in other organs (Fig. 5C). Selective gene
expression in tumors is probably mediated by sufﬁcient masking of
CPP activity via increasing PEGylation rate of complexes and tumor sen-
sitive induction of gene expression is achieved via speciﬁc CPP/pDNA
complex activation after removal of PEG by MMP2 cleavage. This ex-
pression proﬁle encouraged us to assess the gene induction mediated
by the cell-penetrating peptides carrying increasing size of PEGs
(Table 1).
Wedemonstrate that it is possible to enhance or inhibit gene expres-
sion in different organs according to necessity, by using different
PEGylation rates (Fig. 5D–F). For example using PF145 (PEG1000) or
PF146 (PEG2000) at lower PEGylation rates enables to reduce gene ex-
pression levels to baseline levels, at the same time inducing high gene
expression in the lungs. On the other hand, PF144 at PEGylation rate
50% is able to induce uniform gene expression in organs and Neuro2a
tumor (Fig. 5D). Nevertheless, it should be noted that MMP-sensitive
activation depends onMMP levels in particular tumor, i.e. tumor growth
aggressiveness. Therefore, the PEGylation rate should be optimized for
different types of tumors. To summarize, applying this strategy enables
speciﬁc and ﬂexibly adjustable induction of gene expression in different
organs and tumors, therefore representing simple and efﬁcient gene
delivery platform for therapeutic interventions.4. Conclusions
In conclusion, we propose a simple method to functionalize
noncovalent CPP/nucleic acid complexes. As a proof of concept, we
have utilized this strategy for obtaining a tumor-selective gene delivery
vector and effectively induced expression of a reporter gene in tumor
tissues. Importantly, this approach may be extended to other CPPs and
include other types of functional moieties due to the simple ﬂexible
formulation and functionalization of nucleic acid and CPP complexes.Acknowledgment
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